- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Study Reveals Significant Care Gap in SGLT2 Inhibitor Use for Diabetes and HF, Despite Real-World Benefits
![Study Reveals Significant Care Gap in SGLT2 Inhibitor Use for Diabetes and HF, Despite Real-World Benefits Study Reveals Significant Care Gap in SGLT2 Inhibitor Use for Diabetes and HF, Despite Real-World Benefits](https://medicaldialogues.in/h-upload/2022/10/28/750x450_189143-sglt2-inhibitors.webp)
Recent study highlights a significant care gap due to the underuse of SGLT2 inhibitors, despite their benefits.
Canada: A recent population-level cohort study conducted in Alberta, Canada, sheds light on the real-world impact of sodium-glucose cotransporter-2 inhibitors (SGLT2i) in adults with diabetes and heart failure (HF). The study that reviewed patient data across the province found that only 10% of individuals with both conditions were prescribed SGLT2 inhibitors, despite the clear benefits these medications offer.
The study, published in the Canadian Journal of Diabetes, highlights a significant care gap due to the underuse of SGLT2 inhibitors despite their association with real-world reductions in heart failure hospitalizations and all-cause mortality.
"The study underscores the opportunity to enhance management and the need for tools and strategies to optimize the use of SGLT2 inhibitors in individuals with diabetes and heart failure," the researchers wrote.
SGLT2 inhibitors are a class of diabetes medications that prevent glucose reabsorption in the kidneys, thus lowering blood sugar levels. Emerging research has also highlighted their cardiovascular benefits, particularly for patients with heart failure.
Since 2016, clinical guidelines have endorsed SGLT2 inhibitors for individuals with type 2 diabetes and heart failure. Sonia Butalia, University of Calgary, Calgary, Alberta, Canada, and colleagues examined SGLT2i dispensation, factors associated with dispensation, HF hospitalization, and all-cause mortality in people with diabetes and HF.
For this purpose, a retrospective, population-based cohort study was conducted to identify individuals with diabetes and heart failure in Alberta, Canada, from 2014 to 2017. These patients were tracked for at least three years to monitor SGLT2 inhibitor dispensation and outcomes. Multivariate logistic regression was employed to evaluate factors influencing SGLT2i dispensation, while propensity scores and regression adjustments were used to estimate the impact of SGLT2i treatment on heart failure hospitalizations.
The study revealed the following findings:
- Among 22,025 individuals with diabetes and heart failure (43.4% women, mean age 74.7±11.8 years), only 10.2% were dispensed an SGLT2i.
- Male sex, age <65 years, a higher baseline glycated hemoglobin, no chronic kidney disease, presence of atherosclerotic cardiovascular disease, and urban residence were associated with SGLT2i dispensation.
- Lower heart failure hospitalization rates were observed in those with SGLT2i dispensation (548.1 per 100 person-years) versus those without (813.5 per 1,000 person-years) and lower all-cause mortality in those with an SGLT2i than in those without (48.5 per 1,000 person-years versus 206.1 per 1,000 person-years).
- Regression adjustment found that SGLT2i therapy was associated with a 23% reduction in hospitalization.
'Our study reveals a significant care gap in the underuse of SGLT2 inhibitors, with only 1 in 10 individuals with diabetes and established heart failure receiving these medications. Despite this, SGLT2 inhibitors were linked to notable real-world reductions in heart failure hospitalizations and all-cause mortality," the researchers concluded.
"This underscores a major opportunity to enhance cardiovascular management for people with diabetes, highlighting the urgent need for tools and strategies to optimize the use of SGLT2 inhibitors in this population."
Reference:
Butalia, S., Wen, C., Sigal, R., Senior, P., Quan, H., Chu, L. M., Yeung, R. O., & Kaul, P. (2024). Real-world Use and Outcomes of Sodium-Glucose Cotransporter-2 Inhibitors in Adults With Diabetes and Heart Failure: A Population-level Cohort Study in Alberta, Canada. Canadian Journal of Diabetes, 48(5), 305-311.e1. https://doi.org/10.1016/j.jcjd.2024.03.004
MSc. Biotechnology
Medha Baranwal joined Medical Dialogues as an Editor in 2018 for Speciality Medical Dialogues. She covers several medical specialties including Cardiac Sciences, Dentistry, Diabetes and Endo, Diagnostics, ENT, Gastroenterology, Neurosciences, and Radiology. She has completed her Bachelors in Biomedical Sciences from DU and then pursued Masters in Biotechnology from Amity University. She has a working experience of 5 years in the field of medical research writing, scientific writing, content writing, and content management. She can be contacted at  editorial@medicaldialogues.in. Contact no. 011-43720751
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: editorial@medicaldialogues.in. Contact no. 011-43720751